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that were related to ciprofloxacin by the treating doctors 
(personal communication). Apart from the seven patients 
reported here, we are also following up three patients who 
received ciprofloxacin inadvertently during the first trimester 
of pregnancy; one of these women has delivered a healthy 
baby who has had normal linear growth for first 6 months. 
Although we cannot make any definite conclusions from our 
limited data, we believe use of ciprofloxacin in patients with 
MDREF in second-trimester and third-trimester 
pregnancies may be justified when no clearly safe and 
effective alternative is available. 
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Evidence for HIV-1 group O infection in 
Nigeria 
SIR-Dada and colleagues (June 3, p 1436) report that no 
HIV-1 group O infection was found in Nigeria. We report 
here the preliminary data of a study in the Cross River state 
in Nigeria. This region, one of 30 Nigerian states, is located 
in the south-eastern part of the country and borders 
Cameroon. Most HIV-1 group O infections have been 
reported from Cameroon and a few cases from Gabon.' ' 
Between 1992 and 1994, a total of 2083 serum samples 
were obtained for a sentinel surveillance study from 
pregnant women, patients with tuberculosis, infectious 
diseases, sexually transmitted disease, and commercial sex 
workers. Of these samples 183 were positive for HIV-ie, a 
positive reaction with the Wellcozyme HIV-l/HIV-2 test 
(Murex Diagnostics, UK) and HIVCHECK (Ortho 
Diagnostics, USA) tests; 87 were indeterminate for HIV 
antibodies-ie, only antibodies to gag andor pol proteins by 
westem blot; and 1813 were negative for HIV. All samples 
were tested for the presence of HIV-1 group O antibodies by 
an ELISA based on synthetic peptides derived from the V3 
loop of the envelope proteins representing group O viruses 
(ANT70 and MVP5180).1*2 Samples reactive by ELISA were 
retested in a line immunoassay (LIA), in which different 
biotinyiated V3 peptides (consensus, MAL, ANT70, VI686 
[a Gabonese HIV-I group O isolate'], and MVP5180) were 
applied as a Streptavidin complex in parallel lines on nylon 
strips (Innogenetics, Belgium). Samples reactive in ELISA 
and LIA were also retested on a specific westem blot for the 
presence of antibodies to gp120 of HIV-1 ANT70, as 
previously described.' 12 of the 2083 serum samples were 
reactive in the V3 ELISA; ten had optical density (OD) 
values around the cut-off, and only two had a higher OD 
value (OD/cut-off ratio 3.5). The ten weakly reactive 
samples showed no reaction with the group O V3 peptides in 
LIA. One of the two other reactive samples had a reaction 
with the ANT70 peptide but reacted simultaneously with 
the consensus and the MAL peptide and had antibodies to 
the gp120 envelope proteins on a specific HIV-1 ANT70 
western blot. The other serum with a high OD value in 
ELISA reacted on LIA only with the V3 peptides from 
group O with a strong reaction to the ANT70 peptide and a 
weaker reaction with the VI686 and MVP5180 V3 peptides, 
which clearly indicates the presence of HIV-1 group O 
infection. Both samples were from Nigerian AIDS patients. 
These preliminary data indicate that, by contrast with 
Dada and colleagues' report, HIV-1 group O infection is 
present in Nigeria, especially in the Cross River state. 
Despite the geographic location of this state, bordering 
Cameraon, where a prevalence of up to 2% has been 
reported, we showed that HIV-1 group O prevalence was 
low. The spread of these viruses in this and other states of 
Nigeria should be examined to see whether strategies for 
blood screening and serodiagnosis need modification. 
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Surveillance of heterosexually acquired HIV 
infection and AIDS 
SIR-For surveillance purposes, the US Centers for Disease 
Control and Prevention (CDC)' have recently restricted the 
definition of heterosexually acquired HIV infection: 
heterosexual contact cases are those who report specific 
heterosexual contact with a person known to be HIV- 
infected, irrespective of his(her) exposure category, or with a 
person at an increased risk of HIV infection-ie, intravenous 
drug users, male bisexuals, haemophiliacs, or other 
recipients of HIV-contaminated blood products. People 
from countries where heterosexual transmission is presumed 
to be the predominant mode of HIV transmission and those 
who have sex with a person from such countries are no 
longer reported in the USA as having acquired AIDS or HIV 
infection through heterosexual contact. The French 
Direction Genérale de la Santé (DGS) has maintained this 
last category in the definition of heterosexually acquired HIV 
infection.' 
The impact of various definitions of heterosexually 
acquired HIV infection has been evaluated in the hospital- 
based surveillance system of HIV infection in place in 
Aquitaine, south-westem France (2.8 millions inhabitants), 
since 1985.3 HIV-positive patients aged 13 years or older 
who give informed consent are reported by the participating 
physicians, whatever their clinical stage of infection. This 
system accounted for 84% of the cases of HIV infection 
diagnosed in the region from 1991 to 1993.' Once reported, 
all patients are included in the Aquitaine cohort, and all 
exposure categories are represented. Epidemiological data 
obtained by interview and from medical records were 
updated during follow-up. Heterosexually acquired infection 
were considered according to the CDC definition,' the DGS 
definition: probable and possible cases, and two sub- 
categories of the no risk reported or identified category: 
probable cases are those subjects who report heterosexual 
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